Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.98 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.98 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.98 |
| ▸ | APEX1 | P27695 | 1/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.98 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.98 |
| ▸ | HTR1A | P08908 | 2/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.77 |
| ▸ | MAPT | P10636 | 1/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.77 |
| ▸ | DRD2 | P14416 | 1/20 | 0.77 |
| ▸ | TSHR | P16473 | 1/20 | 0.77 |
| ▸ | DRD4 | P21917 | 1/20 | 0.77 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.77 |
| ▸ | DRD3 | P35462 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carmoxirole SCHEMBL31723392 | 1.00 | TDP1 (0.98) | TDP1KDM4EALOX15APEX1KMT2A | |
| Carmoxirole SCHEMBL5606162 | 1.00 | TDP1 (0.98) | TDP1KDM4EALOX15APEX1KMT2A | |
| Carmoxirole SCHEMBL1231058 | 0.99 | TDP1 (1.00) | TDP1KDM4EALOX15APEX1KMT2A | |
| SCHEMBL9581606 | 0.99 | TDP1 (0.96) | TDP1KDM4EALOX15APEX1KMT2A | |
| SCHEMBL9581458 | 0.97 | TDP1 (0.93) | TDP1KDM4EALOX15APEX1KMT2A | |
| SCHEMBL9582676 | 0.93 | TDP1 (0.85) | TDP1KDM4EALOX15APEX1KMT2A | |
| SCHEMBL9581852 | 0.93 | TDP1 (0.85) | TDP1KDM4EALOX15APEX1KMT2A | |
| SCHEMBL9582127 | 0.93 | TDP1 (0.84) | TDP1KDM4EALOX15APEX1KMT2A | |
| SCHEMBL9581872 | 0.93 | TDP1 (0.84) | TDP1KDM4EALOX15APEX1KMT2A | |
| SCHEMBL9581566 | 0.92 | TDP1 (0.84) | TDP1KDM4EALOX15APEX1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 427 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4717276-A2 | OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | University of Canberra (AU) | 2026-04-01 | — | — | EP | claimed |
| EP-3442516-B1 | OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | UNIV CANBERRA (AU) | 2025-11-12 | — | — | EP | claimed |
| US-11890266-B2 | Ophthalmic compositions including levodopa, an antioxidant and an aqueous carrier | UNIVERSITY OF CANBERRA (AU) | 2024-02-06 | — | — | US | claimed |
| US-20220047529-A1 | METHODS OF INHIBITION | UNIVERSITY OF CANBERRA (AU) | 2022-02-17 | — | — | US | claimed |
| EP-3849533-A1 | METHODS OF INHIBITION | University of Canberra (AU) | 2021-07-21 | — | — | EP | claimed |
| US-20210213001-A1 | METHOD OF TREATING A SLEEP BREATHING DISORDER | MONASH UNIVERSITY (AU) | 2021-07-15 | — | — | US | claimed |
| EP-3846794-A1 | METHOD OF TREATING A SLEEP BREATHING DISORDER | Monash University (AU) | 2021-07-14 | — | — | EP | claimed |
| US-20210077443-A1 | OPHTHALMIC COMPOSITIONS INCLUDING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | UNIVERSITY OF CANBERRA (AU) | 2021-03-18 | — | — | US | claimed |
| US-10874629-B2 | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | UNIVERSITY OF CANBERRA (AU) | 2020-12-29 | — | — | US | claimed |
| WO-2020051648-A1 | METHODS OF INHIBITION | UNIVERSITY OF CANBERRA (AU) | 2020-03-19 | — | — | WO | claimed |
| EP-1742624-A2 | DOPAMINE-AGONIST COMBINATION THERAPY WITH SEDATIVES FOR IMPROVING SLEEP QUALITY | Sepracor, Inc. (US) | 2007-01-17 | — | — | EP | claimed |
| WO-2006113485-A2 | AMINERGIC PHARMACEUTICAL COMPOSITIONS AND METHODS | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2006-10-26 | — | — | WO | claimed |
| US-20050267176-A1 | Dopamine-agonist combination therapy for improving sleep quality | SEPRACOR INC. (US) | 2005-12-01 | — | — | US | claimed |
| WO-2005079851-A2 | DOPAMINE-AGONIST COMBINATION THERAPY WITH SEDATIVES FOR IMPROVING SLEEP QUALITY | SEPRACOR, INC. (US) | 2005-09-01 | — | — | WO | claimed |
| WO-2004041207-A2 | GHB TREATMENT METHODS | BAYLOR RESEARCH INSTITUTE (US) | 2004-05-21 | — | — | WO | claimed |
| EP-1397134-A2 | COMBINATION OF A DOPAMINE D2-RECEPTOR AGONIST AND TIOTROPIUM OR A DERIVATIVE THEROF FOR TREATING OBSTRUCTIVE AIRWAYS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-03-17 | — | — | EP | claimed |
| WO-2002096422-A2 | COMBINATION OF A DOPAMINE D2-RECEPTOR AGONIST AND TIOTROPIUM OR A DERIVATIVE THEREOF FOR TREATING OBSTRUCTIVE AIRWAYS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-12-05 | — | — | WO | claimed |
| WO-2000054773-A1 | DOPAMINE AGONISTS IN COMBINATION WITH NITRIC OXIDE DONORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2000-09-21 | — | — | WO | claimed |
| WO-1998022114-A1 | A METHOD FOR PROMOTING TISSUE REPAIR | DUMEX-ALPHARMA A/S (DK) | 1998-05-28 | — | — | WO | claimed |
| US-5256673-A | Indole-3-yl-A-tetrahydropyridyl or piperidyl compounds | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1993-10-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267176-A1 | Dopamine-agonist combination therapy for improving sleep quality | DRD2, DRD1, HTR5A | TDP1 2656/4885KDM4E 342/4885ALOX15 2470/4885 |
| US-20210213001-A1 | METHOD OF TREATING A SLEEP BREATHING DISORDER | KCNQ4, KCNQ3, KCNQ1 | TDP1 2750/4885KDM4E 242/4885ALOX15 3165/4885 |
| US-20220047529-A1 | METHODS OF INHIBITION | SLC6A3, DBH, SNCA | TDP1 2477/4885KDM4E 1444/4885ALOX15 3154/4885 |
| US-11890266-B2 | Ophthalmic compositions including levodopa, an antioxidant and an aqueous carrier | TTPA, TST, TXN2 | TDP1 533/4885KDM4E 1593/4885ALOX15 195/4885 |
| US-10874629-B2 | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | COMT, LRRK2, PARK7 | TDP1 772/4885KDM4E 2126/4885ALOX15 262/4885 |
| US-20210077443-A1 | OPHTHALMIC COMPOSITIONS INCLUDING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | TTPA, TST, TXN2 | TDP1 533/4885KDM4E 1593/4885ALOX15 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.